About cellvie

cellvie specializes in Therapeutic Mitochondria Transplantation, a technique that augments and replaces dysfunctional mitochondria to restore cellular energy metabolism. The company targets ischemia-reperfusion injury, a critical condition affecting organ transplantation and heart attacks, aiming to reduce delayed graft function in kidney recipients.

```xml <problem> Ischemia-reperfusion injury, occurring when blood flow is interrupted and then restored, poses a significant challenge in medical procedures like organ transplantation and during events such as heart attacks and strokes. This injury can lead to complications such as delayed graft function in kidney transplant recipients. </problem> <solution> cellvie is developing Therapeutic Mitochondria Transplantation, a method to augment and replace dysfunctional mitochondria within cells, thereby restoring cellular energy metabolism. This approach aims to address ischemia-reperfusion injury, particularly in the context of kidney transplantation, by reducing the incidence of delayed graft function. By reinvigorating the cell's energy production, this technology offers a novel treatment modality for conditions where mitochondrial dysfunction plays a key role. The company's focus extends beyond ischemia-reperfusion injury to explore applications in slowing or reversing degenerative processes associated with aging. </solution> <features> - Therapeutic Mitochondria Transplantation technique to augment and replace dysfunctional mitochondria. - Targeted application for ischemia-reperfusion injury arising in heart attacks, stroke, surgical procedures, and organ transplantation. - Focus on reducing delayed graft function in kidney transplant recipients. - Aims to restore cellular energy metabolism by directly addressing mitochondrial function. </features> <target_audience> The primary target audience includes patients undergoing organ transplantation, particularly kidney transplantation, and individuals at risk of ischemia-reperfusion injury due to heart attacks, strokes, or surgical procedures. </target_audience> ```

What does cellvie do?

Where is cellvie located?

cellvie is based in Zürich, Switzerland.

When was cellvie founded?

cellvie was founded in 2018.

How much funding has cellvie raised?

cellvie has raised 10530000.

Location

Zürich, Switzerland

Founded

2018

Funding

10530000

Employees

9 employees

Major Investors

Taiho Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

cellvie

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

cellvie.bio 3K+

Crunchbase

Founded 2018 – Zürich, Switzerland

Funding

Estimated Funding

$10M+

Major Investors

Taiho Ventures

Team (5+)

No team information available.

Company Description

Problem

Ischemia-reperfusion injury, occurring when blood flow is interrupted and then restored, poses a significant challenge in medical procedures like organ transplantation and during events such as heart attacks and strokes. This injury can lead to complications such as delayed graft function in kidney transplant recipients.

Solution

cellvie is developing Therapeutic Mitochondria Transplantation, a method to augment and replace dysfunctional mitochondria within cells, thereby restoring cellular energy metabolism. This approach aims to address ischemia-reperfusion injury, particularly in the context of kidney transplantation, by reducing the incidence of delayed graft function. By reinvigorating the cell's energy production, this technology offers a novel treatment modality for conditions where mitochondrial dysfunction plays a key role. The company's focus extends beyond ischemia-reperfusion injury to explore applications in slowing or reversing degenerative processes associated with aging.

Features

Therapeutic Mitochondria Transplantation technique to augment and replace dysfunctional mitochondria.

Targeted application for ischemia-reperfusion injury arising in heart attacks, stroke, surgical procedures, and organ transplantation.

Focus on reducing delayed graft function in kidney transplant recipients.

Aims to restore cellular energy metabolism by directly addressing mitochondrial function.

Target Audience

The primary target audience includes patients undergoing organ transplantation, particularly kidney transplantation, and individuals at risk of ischemia-reperfusion injury due to heart attacks, strokes, or surgical procedures.